The maker of widely used blood thinner Eliquis on Friday sued the U.S. government over a provision in the Inflation Reduction Act that would let Medicare negotiate drug prices, becoming the second ...

A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to ...

Moreover, Eliquis cost the U.S. government more than $12 billion in 2021 according to the Centers for Medicare & Medicaid Services. Pfizer has also been in the race to develop a diabetes/weight ...

Pfizer's new product lineup could allow the pharmaceutical giant to push its dividend steadily higher for another 15 years.

These prices will be enacted in January 2026. The 10 drugs selected to undergo negotiations include two blood thinners, Eliquis and Xarelto; three diabetes drugs, Januvia, Jardiance and Fiasp ...

Opdivo and Eliquis will likely face heavy generic drug ... Room to raise U.S. cigarette prices to offset declining volumes. Diversification outside cigarettes into other tobacco products reduces ...

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the ...

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement ...

The first session, on Eliquis, is set for Oct. 30 ... was signed into law last year allows Medicare to directly negotiate prices of certain high-expenditure, single-source drugs without generic ...

Longer term, the federal Medicare program is beginning to negotiate prices for a limited number of medications, including Eliquis. The first negotiated prices are effective in 2026. Democrats ...

Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key ...